High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company’s drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
Health Industry
2,521-2,540 of 4,033 results
-
-
Open Your Mouth And Say Goo-Goo: Dentists Treating Ever-Younger Patients
A shift in dental guidelines encourages first dental visits for infants as young as 6 months, or when the first baby teeth emerge. That makes some dentists uncomfortable.
-
As Care Shifts From Hospital To Home, Guarding Against Infection Falls To Families
Despite a lack of medical training, relatives increasingly are assigned complex, risky medical tasks at home, such as maintaining catheters. If done incorrectly, blood clots, infections, even death can result.
-
Trump’s Deadline On ‘Dreamers’ Reverberates Through Health Industries
From medical students to home health aides, the loss of DACA could deal a blow to the health care workforce, industry leaders suggest.
-
The Orphan Drug Machine
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
-
This Gift Voucher Might Just Get You A Kidney
A retired California judge came up with the idea of donating his kidney to a stranger now to maximize his grandson’s prospects for such a donation later. The idea caught on.
By Fran Kritz -
Reporter’s Notebook: In Health Care, A Good Price (Or Any Price) Is Hard To Find
Not only are health prices hidden, industry players are contractually obligated to keep them secret. That’s why answering a simple question — how much does it cost to have a baby in Mountain View, Calif.? — became a journalistic quest.
By Jenny Gold -
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Repeal & Replace Watch
Postcard From The Hill: Senators Shelve Histrionics In Search Of Obamacare Fix
The Senate health committee is putting aside partisan bickering this month to seek a legislative remedy to a possible spike in Obamacare premiums this fall.
By Rachel Bluth -
Quiz: How Well Are You Paying Attention?
To strengthen your core knowledge of health care policy, it helps to be a regular reader of Kaiser Health News. Here's a pop quiz to gauge what you have learned.
-
Guess Who Pays The Price When Hospital Giants Hire Your Private Practitioner?
Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.
By Jenny Gold -
Meningitis B Vaccine’s High Price Poses A Health Care Conundrum For College-Bound
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
-
5 Governors Press Congress For Fast Bucks To Secure Obamacare Market In 2018
State leaders tell senators that federal dollars are needed this fall to keep insurers participating in Obamacare next year and prevent big hikes in premiums.
By Julie Rovner and Rachel Bluth -
Shedding New Light On Hospice Care: No Need To Wait For The ‘Brink Of Death’
Hospice care often prompts fear and misunderstanding, but the services provided can lead to less pain and trauma at the end of life.
-
Repeal & Replace Watch
Vital Health Officials You’ve Never Heard Of: Insurance Commissioners In The Hot Seat
The fate of the Affordable Care Act’s individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
-
How Below-The-Radar Mergers Fuel Health Care Monopolies
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
By Jay Hancock -
Another Way For Anti-Vaxxers To Skip Shots For Schoolkids: A Doctor’s Note
No longer able to get exemptions for personal beliefs in California, parents opposed to inoculations seem to be obtaining medical exemptions for their children, according to a new study.
-
Rep. Chris Collins’ Australian Stock Bet Looks Bleaker
Innate Immunotherapeutics, the Australian biotech firm whose largest shareholder is Buffalo, N.Y.-area congressman Chris Collins, said it expects to close after its multiple sclerosis drug failed in trials.
By Rachel Bluth -
St. Kitts Launches Probe Of Herpes Vaccine Tests On U.S. Patients
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
-
Pioneering Cancer Gene Therapy Gets Green Light — And $475,000 Price Tag
The USA's first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
By Liz Szabo